Pfizer/BioNTech has initiated its application to the US Food and Drug Administration for full FDA approval of its Covid-19 vaccine for people ages 16 and older, the companies said Friday. This is the ...
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
Amid uncertainty over how the Trump administration would approach mRNA COVID-19 vaccines for the upcoming respiratory virus season, the FDA has approved updated shots from Pfizer and Moderna. But ...
The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...
U.S.-based pharmaceutical giant German biotech company BioNTech were already collaborating to come up with a flu vaccine ...
Pfizer is selling its remaining stake in COVID-19 vaccine partner BioNTech. The U.S. drugmaker is offering about 4.55 million American depositary receipts in an overnight block trade, marketed at ...
Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results